Search

Displaying results 981 - 990 of 10000 in total
  1. Drug

    Pumactant

    go.drugbank.com/drugs/DB04955
    Experimental

    Pumactant is a synthetic surfactant used for treating respiratory distress syndrome in neonates.

  2. Drug

    Rivoceranib

    go.drugbank.com/drugs/DB14765
    Investigational

    Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).

  3. Drug

    Fosgemcitabine palabenamide

    go.drugbank.com/drugs/DB15057
    Investigational

    NUC-1031 is under investigation in clinical trial NCT03610100 (Acelarin First Line Randomised Pancreatic Study).

    Synonyms: L-ALANINE, N-(2'-DEOXY-2',2'-DIFLUORO-P-PHENYL-5'-CYTIDYLYL)-, PHENYLMETHYL ESTER, N-[[P(S)]-2'-deoxy-2',2'-difluoro-P-phenyl-5'-cytidylyl]-L-alanine phenylmethyl ester
  4. Drug

    Buspirone

    go.drugbank.com/drugs/DB00490
    ApprovedInvestigational

    It has also been used as a second-line therapy for unipolar depression when the use of selective serotonin reuptake inhibitors (SSRIs) is deemed clinically inadequate or inappropriate. … [A180985] First synthesized in 1968 then patented in 1975,[L7375] it is commonly marketed under the brand name Buspar®.

  5. Drug

    Vestronidase alfa

    go.drugbank.com/drugs/DB12366
    ApprovedInvestigational

    Vestronidase alfa, or vestronidase alfa-vjbk, is a recombinant human lysosomal beta glucuronidase that is a purified enzyme produced by recombinant DNA technology in a Chinese hamster ovary cell line. … In clinical trials, vestronidase alfa treatment demonstrated improvement and stabilization in motor symptoms by increasing the patients' ability to walk longer distances in comparison to treatment with

  6. Drug

    Reslizumab

    go.drugbank.com/drugs/DB06602
    ApprovedInvestigational

    Patients often experience persistent or exacerbating symptoms overtime despite conventional first-line therapies available. … Cinqair is indicated as an add-on maintenance therapy for adults with severe asthma with an eosinophilic phenotype.

  7. Drug

    Insulin lispro

    go.drugbank.com/drugs/DB00046
    ApprovedInvestigational

    Insulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able … in position B29 is replaced by proline.

    Mixtures: Humalog Mix 25 (pen), Humalog Mix 25 (pen)Categories: Drugs Used in Diabetes
  8. Drug

    Cobamamide

    go.drugbank.com/drugs/DB11191
    ApprovedNutraceutical

    in the mitochondria [L2053]. … Please refer to the entry [DB00115] for more information on this entry.

    Mixtures: Enl, EnLyte Extra-LN
  9. Drug

    Rituximab

    go.drugbank.com/drugs/DB00073
    ApprovedInvestigational

    On November 28, 2018, the US FDA approved _Truxima_, the first biosimilar to Rituxan (Rituximab) [L4808]. … Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes.

  10. Drug

    Peginterferon beta-1a

    go.drugbank.com/drugs/DB09122
    ApprovedInvestigational

    [L5801] MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men. … It was originally approved by the FDA in 2014 for subcutaneous use, and was approved for intramuscular use in January 2021.

    Mixtures: Plegridy Pen, Plegridy PenCategories: Compounds used in a research, industrial, or household setting